Z 360

Drug Profile

Z 360

Alternative Names: Z-360

Latest Information Update: 12 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zeria
  • Class Antineoplastics; Antiulcers; Benzodiazepines; Benzoic acids; Gastric antisecretories; Urea compounds
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Discontinued Peptic ulcer

Most Recent Events

  • 01 Mar 2017 Zeria completes a phase II trial in Pancreatic cancer (Metastatic disease, Combination therapy) in Japan, South Korea & Taiwan (NCT02117258)
  • 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in United Kingdom (PO)
  • 26 Apr 2014 Phase-II clinical trials in Pancreatic cancer (metastatic disease; combination therapy) in Japan, South Korea & Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top